4.2 Review

Daily life impairments associated with childhood/adolescent attention-deficit/hyperactivity disorder as recalled by adults: results from the European Lifetime Impairment Survey

期刊

CNS SPECTRUMS
卷 20, 期 2, 页码 112-121

出版社

CAMBRIDGE UNIV PRESS
DOI: 10.1017/S1092852914000078

关键词

ADHD; diagnosis; functional impairment; Lifetime Impairment Survey; treatment

资金

  1. Shire
  2. Janssen-Cilag
  3. Vifor
  4. QBTech
  5. Flynn Pharma
  6. Eli Lilly
  7. Akili Interactive Labs
  8. Alcobra
  9. VAYA Pharma
  10. SynapDx
  11. National Institutes of Health (NIH)
  12. Otsuka
  13. McNeil
  14. Janssen
  15. Novartis
  16. Pfizer
  17. Medice
  18. German Research Foundation
  19. German Ministry of Education and Research
  20. Medical Research Council [G9817803B] Funding Source: researchfish

向作者/读者索取更多资源

Introduction. The Lifetime Impairment Survey, conducted in Europe, assessed impairment and symptoms of attentiondeficit/ hyperactivity disorder (ADHD) in childhood, and experiences of ADHD diagnosis and treatment, as recalled by adults. Methods. Adults with ADHD and without ADHD (control group) were invited to participate in an internet-based survey and report on their childhood experiences. History of ADHD diagnosis was self-reported. Groups were compared using impairment and symptom scales. Results. Overall, 588 adults with ADHD and 736 without ADHD participated. Mean (standard deviation [SD]) age at diagnosis of ADHD was 20.0 (12.6) years (median 18.0) following consultation with 3.8 (5.1) doctors (median 2) over 44.6 (69.3) months (median 17.0). A total of 64.1% (377/588) of adults with ADHD reported frustration or difficulties during the diagnostic process. The ADHD group had a higher mean (SD) score versus control for general (3.3 [1.2] vs 2.1 [1.2]; p<0.001) and school impairment (2.8 [0.7] vs 2.3 [0.6]; p < 0.001) but not home impairment (2.1 [0.5] for both groups). Discussion. The survey demonstrated that ADHD had a negative impact on all aspects of childhood investigated, as recalled by adults. Conclusions. These data provide insights into childhood impairments and identify areas for improvement in the management and treatment of ADHD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据